Welcome to TARGIT Collaborative Group



Welcome to the TARGIT Collaborative Group (TCG) Quality Collaborative (QC).

We thank you for your interest in joining our quality collaborative. We strive to engage with fellow innovators in order to improve patient care.

The TCG QC is dedicated towards enhancing the outcome of patients treated with breast conserving surgery (BCS) and targeted intraoperative radiotherapy (TARGIT). The information you provide will allow us to gather critical data that will help facilitate our primary objective of utilizing longitudinal outcome analysis to improve the quality of care and safety of patients treated with BCS and TARGIT.

We are currently in the Beta phase of our initiative. We are seeking up to 10 sites to join us for this stage in our development. Interested parties will contact our Coordinator, Mark Leshyk, EMAIL coordinatorqc@targitcollaborative.org - for questions and submission of required materials.

The QC Committee will in turn provide a decision on a party's application within 30 days of all required document submission to our Coordinator. If a party is not selected amongst the initial Beta sites, that does not definitively exclude that party's capacity to join us when we are at full operational status. It may simply mean that the party will be added after the Beta phase has ended and QC is at full operational status. We will maintain a status of our QC on our landing page site at all times.

<u>Note</u> – REGARDLESS OF PHASE, WE STRONGLY ENCOURAGE ALL INTERESTED PARTIES TO REACH OUT. DEPENDING ON REQUIREMENTS SURROUNDING DATA USE AGREEMENTS (DUAS) AND POSSIBLE IRB APPROVALS), THE ENTRY PROCESS MAY REQUIRE A CONSIDERABLE TIME COMMITMENT.

SITES WILL BE ADDED ONLY UPON APPROVAL OF ALL REQUIRED ELEMENTS AS DETERMINED BY THE QC COMMITTEE. SITES ACKNOWLEDGE THAT THE RESPONSIBILITY TO DETERMINE THE NECESSITY OF LOCAL REGULATORY REQUIREMENTS IS THEIRS AND THEIRS ALONE, AND AGREE TO PROVIDE THE TCG COMITTEE SUBSTANTIATING MATERIAL UPON SUCH DETERMINATION.

The TCG QC HEREBY MAINTAINS NO RESPONSIBILTY IN DELAYS OF ACCEPTANCE AND/OR DENIAL OF ENTRY DUE TO ERRORS AND INSUFFICIENCIES COMMITTED BY THE INTERESTED PARTIES.



Warm regards,

TARGIT Collaborative Group Quality Collaborative

Co-Chair

Dennis R. Holmes, M.D., F.A.C.S.
Co-Chair of the TARGIT U.S. Registry
Adventist Health Glendale
Medical Director, Breast Surgery Program
1505 Wilson Terrace, Suite 150
Glendale, CA 91206
drholmesmd@me.com

Co-Chair

William Small, Jr., MD, FACRO, FACR, FASTRO
Professor and Chairman
Department of Radiation Oncology
Stritch School of Medicine Loyola University Chicago
Director, Cardinal Bernardin Cancer Center
2160 S 1st Ave
Maguire Center, Rm 2944
Maywood, IL 60153
wmsmall@lumc.edu